These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 27856406)

  • 21. Protocol for a cluster randomised placebo-controlled trial of adjunctive ivermectin mass drug administration for malaria control on the Bijagós Archipelago of Guinea-Bissau: the MATAMAL trial.
    Hutchins H; Bradley J; Pretorius E; Teixeira da Silva E; Vasileva H; Jones RT; Ndiath MO; Dit Massire Soumare H; Mabey D; Nante EJ; Martins C; Logan JG; Slater H; Drakeley C; D'Alessandro U; Rodrigues A; Last AR
    BMJ Open; 2023 Jul; 13(7):e072347. PubMed ID: 37419638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A field bioassay for assessing ivermectin bio-efficacy in wild malaria vectors.
    Ominde KM; Kamau Y; Karisa J; Muturi MN; Kiuru C; Wanjiku C; Babu L; Yaah F; Tuwei M; Musani H; Ondieki Z; Muriu S; Mwangangi J; Chaccour C; Maia MF
    Malar J; 2023 Sep; 22(1):291. PubMed ID: 37777725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mass Drug Administration With High-Dose Ivermectin and Dihydroartemisinin-Piperaquine for Malaria Elimination in an Area of Low Transmission With High Coverage of Malaria Control Interventions: Protocol for the MASSIV Cluster Randomized Clinical Trial.
    Dabira ED; Soumare HM; Lindsay SW; Conteh B; Ceesay F; Bradley J; Kositz C; Broekhuizen H; Kandeh B; Fehr AE; Nieto-Sanchez C; Ribera JM; Peeters Grietens K; Smit MR; Drakeley C; Bousema T; Achan J; D'Alessandro U
    JMIR Res Protoc; 2020 Nov; 9(11):e20904. PubMed ID: 33211022
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ivermectin treatment in humans for reducing malaria transmission.
    de Souza DK; Thomas R; Bradley J; Leyrat C; Boakye DA; Okebe J
    Cochrane Database Syst Rev; 2021 Jun; 6(6):CD013117. PubMed ID: 34184757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of ivermectin for the treatment of Plasmodium falciparum infections in asymptomatic male and female Gabonese adults - a pilot randomized, double-blind, placebo-controlled single-centre phase Ib/IIa clinical trial.
    Ekoka Mbassi D; Mombo-Ngoma G; Held J; Okwu DG; Ndzebe-Ndoumba W; Kalkman LC; Ekoka Mbassi FA; Pessanha de Carvalho L; Inoue J; Akinosho MA; Dimessa Mbadinga LB; Yovo EK; Mordmüller B; Kremsner PG; Adegnika AA; Ramharter M; Zoleko-Manego R
    EBioMedicine; 2023 Nov; 97():104814. PubMed ID: 37839134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proof-of-concept study for a long-acting formulation of ivermectin injected in cattle as a complementary malaria vector control tool.
    Pooda SH; Moiroux N; Porciani A; Courjaud AL; Roberge C; Gaudriault G; Sidibé I; Belem AMG; Rayaissé JB; Dabiré RK; Mouline K
    Parasit Vectors; 2023 Feb; 16(1):66. PubMed ID: 36788608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.
    Vallejos J; Zoni R; Bangher M; Villamandos S; Bobadilla A; Plano F; Campias C; Chaparro Campias E; Achinelli F; Guglielmone HA; Ojeda J; Medina F; Farizano Salazar D; Andino G; Ruiz Diaz NE; Kawerin P; Meza E; Dellamea S; Aquino A; Flores V; Martemucci CN; Vernengo MM; Martinez SM; Segovia JE; Aguirre MG
    Trials; 2020 Nov; 21(1):965. PubMed ID: 33234158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mass drug administration of ivermectin in south-eastern Senegal reduces the survivorship of wild-caught, blood fed malaria vectors.
    Sylla M; Kobylinski KC; Gray M; Chapman PL; Sarr MD; Rasgon JL; Foy BD
    Malar J; 2010 Dec; 9():365. PubMed ID: 21171970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Phase II Pilot Trial to Evaluate
    Noudjiegbe AN; Alikekere FN; Tchehouenou H; Langa Y; Ota DS; Degbelo JE; Allabi ACE
    Evid Based Complement Alternat Med; 2020; 2020():8715021. PubMed ID: 32215047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial.
    Hamaluba M; van der Pluijm RW; Weya J; Njuguna P; Ngama M; Kalume P; Mwambingu G; Ngetsa C; Wambua J; Boga M; Mturi N; Lal AA; Khuroo A; Taylor WRJ; Gonçalves S; Miotto O; Dhorda M; Mutinda B; Mukaka M; Waithira N; Hoglund RM; Imwong M; Tarning J; Day NPJ; White NJ; Bejon P; Dondorp AM
    Lancet Infect Dis; 2021 Oct; 21(10):1395-1406. PubMed ID: 34111412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of larval exposure to sublethal doses of ivermectin on adult fitness and susceptibility to ivermectin in Anopheles gambiae s.s.
    Kiuru C; Ominde K; Muturi M; Babu L; Wanjiku C; Chaccour C; Maia MF
    Parasit Vectors; 2023 Aug; 16(1):293. PubMed ID: 37605264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of ivermectin metabolites and their activity against Anopheles stephensi mosquitoes.
    Kern C; Müller P; Chaccour C; Liechti ME; Hammann F; Duthaler U
    Malar J; 2023 Jun; 22(1):194. PubMed ID: 37355605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety.
    Chaccour C; Hammann F; Rabinovich NR
    Malar J; 2017 Apr; 16(1):161. PubMed ID: 28434401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of oral anthelmintics on the survivorship and re-feeding frequency of anthropophilic mosquito disease vectors.
    Kobylinski KC; Deus KM; Butters MP; Hongyu T; Gray M; da Silva IM; Sylla M; Foy BD
    Acta Trop; 2010 Nov; 116(2):119-26. PubMed ID: 20540931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Filling gaps on ivermectin knowledge: effects on the survival and reproduction of Anopheles aquasalis, a Latin American malaria vector.
    Sampaio VS; Beltrán TP; Kobylinski KC; Melo GC; Lima JB; Silva SG; Rodriguez ÍC; Silveira H; Guerra MG; Bassat Q; Pimenta PF; Lacerda MV; Monteiro WM
    Malar J; 2016 Sep; 15(1):491. PubMed ID: 27660149
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety, Pharmacokinetics, and Mosquito-Lethal Effects of Ivermectin in Combination With Dihydroartemisinin-Piperaquine and Primaquine in Healthy Adult Thai Subjects.
    Kobylinski KC; Jittamala P; Hanboonkunupakarn B; Pukrittayakamee S; Pantuwatana K; Phasomkusolsil S; Davidson SA; Winterberg M; Hoglund RM; Mukaka M; van der Pluijm RW; Dondorp A; Day NPJ; White NJ; Tarning J
    Clin Pharmacol Ther; 2020 May; 107(5):1221-1230. PubMed ID: 31697848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.
    West African Network for Clinical Trials of Antimalarial Drugs (WANECAM)
    Lancet; 2018 Apr; 391(10128):1378-1390. PubMed ID: 29606364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial.
    van der Pluijm RW; Tripura R; Hoglund RM; Pyae Phyo A; Lek D; Ul Islam A; Anvikar AR; Satpathi P; Satpathi S; Behera PK; Tripura A; Baidya S; Onyamboko M; Chau NH; Sovann Y; Suon S; Sreng S; Mao S; Oun S; Yen S; Amaratunga C; Chutasmit K; Saelow C; Runcharern R; Kaewmok W; Hoa NT; Thanh NV; Hanboonkunupakarn B; Callery JJ; Mohanty AK; Heaton J; Thant M; Gantait K; Ghosh T; Amato R; Pearson RD; Jacob CG; Gonçalves S; Mukaka M; Waithira N; Woodrow CJ; Grobusch MP; van Vugt M; Fairhurst RM; Cheah PY; Peto TJ; von Seidlein L; Dhorda M; Maude RJ; Winterberg M; Thuy-Nhien NT; Kwiatkowski DP; Imwong M; Jittamala P; Lin K; Hlaing TM; Chotivanich K; Huy R; Fanello C; Ashley E; Mayxay M; Newton PN; Hien TT; Valecha N; Smithuis F; Pukrittayakamee S; Faiz A; Miotto O; Tarning J; Day NPJ; White NJ; Dondorp AM;
    Lancet; 2020 Apr; 395(10233):1345-1360. PubMed ID: 32171078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What does not kill it makes it weaker: effects of sub-lethal concentrations of ivermectin on the locomotor activity of Anopheles aquasalis.
    Sampaio VS; Rivas GBDS; Kobylinski K; Pinilla YT; Pimenta PFP; Lima JBP; Bruno RV; Lacerda MVG; Monteiro WM
    Parasit Vectors; 2017 Dec; 10(1):623. PubMed ID: 29282130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.